explore -WSS

explore

author：entertainment 2025-09-29 00:39:10 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Doulas covered by Medicaid under New York's new plan

hotspot

WSS

Testing GLP

Idaho abortion case may prompt more restrictions in other states

Cancer, immunology, HIV research ensnared in fetal tissue politics

Surgeons perform first xenotransplant using CRISPR'd pig kidney

New Medicare drug pricing powers could soon be upended in court

Asbestos ban is immediate, but health effects will linger for decades

explore

explore

focus

Cancer drug shortages should be causing more outrage

Biotech reporter’s notebook: A sunnier mood at JPM 2024

United colonoscopy coverage change 'may cost lives,' doctors say

Steward Health Care expansion into Malta flopped

Supreme Court strikes down use of affirmative action

Bring on the sabbaticals for nurses

Cancer drug shortages should be causing more outrage

The SUPPORT Act is critical to fighting the opioid crisis

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

'Patient friction coefficient' can gauge a clinical trial's patient burden

hotspot

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

This gene therapy has record $4.25 million price. It's saved children.

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Biotech investment managers search for lucrative opportunities

Steward Health Care expansion into Malta flopped

Fauci’s Covid grilling leads GOP to weigh foreign research rules

hotspot

focus

leisure time

focus